Some experts say oral versions of popular weight-loss drugs such as Wegovy could offer people more flexibility and ...

Shares of Eli Lilly LLY soared 14.3% on April 17 after data from a late-stage study showed that orforglipron achieved the ...

Topline data were announced from a phase 3 trial evaluating orforglipron in adults with T2D and inadequate glycemic control with diet and exercise alone.

A study led by researchers in the University of Florida College of Pharmacy has found that a pair of popular glucose-lowering ...

If you are taking a weight loss medication such as Ozempic, Wegovy, or Zepbound for obesity or other health concerns, you may ...

Novo Nordisk remains an industry leader, and currently offers both a 2.7% dividend yield and compelling value that can work ...

Initially developed to manage blood sugar levels in diabetic patients, GLP-1 agonists have gained popularity for their weight-reducing effects.

A new study reveals a potential link between popular weight loss drugs like Ozempic and an increased risk of depression and ...

For individuals living with type 2 diabetes or struggling with weight loss, Rybelsus has become a popular name in the realm of oral GLP-1 receptor agonists. While its effectiveness in lowering blood ...

Novo Nordisk (NYSE: NVO) has seen revenue soar in recent years thanks to two drugs that have helped people around the world ...

Lilly (LLY) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings ...

New research found hospital visits from Ozempic and Wegovy are rare, but can be serious. Experts explain the finding and ...